Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery

J Cyst Fibros. 2019 Sep;18(5):677-684. doi: 10.1016/j.jcf.2019.06.011. Epub 2019 Jul 11.

Abstract

The last decade has witnessed developments in the CF drug pipeline which are both exciting and unprecedented, bringing with them previously unconsidered challenges. The Task Force group was brought together to consider these challenges and possible strategies to address them. Over the last 18 months, we have discussed internally and gathered views from a broad range of individuals representing patient organisations, clinical and research teams, the pharmaceutical industry and regulatory agencies. In this and the accompanying article, we discuss two main areas of focus: i) optimising trial design and delivery for speed and efficiency; ii) drug development for patients with rare CFTR mutations. We propose some strategies to tackle the challenges ahead and highlight areas where further thought is needed. We see this as the start of a process rather than the end and hope herewith to engage the wider community in seeking solutions to improved treatments for all patients with CF.

Keywords: CFTR modulators; Clinical trial design; Cystic fibrosis.

MeSH terms

  • Clinical Trials as Topic* / methods
  • Clinical Trials as Topic* / standards
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / genetics
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Drug Development* / organization & administration
  • Drug Development* / standards
  • Drug Discovery* / methods
  • Drug Discovery* / trends
  • Humans
  • Membrane Transport Modulators / pharmacology*
  • Mutation
  • Quality Improvement
  • Research Design / standards

Substances

  • Membrane Transport Modulators
  • Cystic Fibrosis Transmembrane Conductance Regulator